Chronic inflammatory demyelinating polyneuropathy: current state of the problem (analysis of a clinical case)
https://doi.org/10.21886/2712-8156-2024-5-2-115-119
Abstract
Chronic inflammatory demyelinating polyneuropathy is an acquired autoimmune disease of the peripheral nervous system, heterogeneous in course and clinical manifestations, which is curable. The variety of forms of the disease and its course cause difficulties in timely diagnosis and initiation of pathogenetic therapy. This article presents a clinical observation of a patient with a wide range of concomitant pathologies, the presence of which significantly complicated the diagnosis and led to delayed prescription of immunosuppressive therapy.
About the Authors
Z. A. Goncharova
Rostov State Medical University
Russian Federation
Russian Federation
Zoya A. Goncharova - Dr. Sci. (Med), Professor of the Department of Nervous Diseases and Neurosurgery.
Rostov-on-Don
N. S. Kovaleva
Rostov State Medical University
Russian Federation
Russian Federation
Natalia S. Kovaleva - Candidate of Medical Sciences, Associate Professor of the Department of Nervous Diseases and Neurosurgery.
Rostov-on-Don
References
1. Goncharova Z.A., Kovaleva N.S. Sensomotornaya demieliniziruyushchaya polineiropatiya v strukture zabolevanii perifericheskoi nervnoi sistemy. Rossiiskii zhurnal boli. 2018;(2):120-121. (In Russ.) eLIBRARY ID: 34966910 EDN: OSPIZT
2. Rizvanova A.S., Grishina D.A., Suponeva N.A. Clinical heterogeneity of chronic inflammatory demyelinating polyneuropathy: diagnostic challenges. Almanac of Clinical Medicine. 2020;48(1):56-64. DOI: 10.18786/2072-0505-2020-48-007
3. Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;90(9):981-987. DOI: 10.1136/jnnp-2019-320314
4. Burd S.G., Lebedeva A.V., Avakyan G.G., Rubleva Yu.V., Pantina N.V., Yurchenko A.V., et al. COVID-19-associated damage of the peripheral nervous system. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(9):15 21. (In Russ.) DOI: 10.17116/jnevro202212209115
5. Trentinaglia M, Lippi G, Salvagno GL, Rispoli MG, De Angelis MV, Castellani F, et al. Peripheral neuropathies during the COVID-19 pandemic: is there a relation? Immunol Res. 2022;70(3):408-413. DOI: 10.1007/s12026-022-09272-1
6. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. Erratum in: Nat Rev Microbiol. 2023;21(6):408. DOI: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13.
7. Suponevа N.А., Naumovа E.S., Gnedovskaya E.V. Chronic inflammatory demyelinating polyneuropathy in adults: diagnostic approaches and first line therapy. Neuromuscular Diseases. 2016;6(1):44-53. (In Russ.) DOI: 10.17650/2222-8721-2016-6-1-44-53
8. Lozeron P, Mariani LL, Dodet P, Beaudonnet G, Théaudin M, Adam C, et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology. 2018;91(2):e143-e152. DOI: 10.1212/WNL.0000000000005777
9. GBD 2019 IMID Collaborators. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019. EClinicalMedicine. 2023;64:102193. DOI: 10.1016/J.ECLINM.2023.102193
Review
For citations:
Goncharova Z.A., Kovaleva N.S. Chronic inflammatory demyelinating polyneuropathy: current state of the problem (analysis of a clinical case). South Russian Journal of Therapeutic Practice. 2024;5(2):115-119. (In Russ.) https://doi.org/10.21886/2712-8156-2024-5-2-115-119
Views:
1792
Email this article 